Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 | P22001 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.52 |
| ▸ | HPGD | P15428 | 3/20 | 0.52 |
| ▸ | BRD4 | O60885 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | NQO2 | P16083 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11375444 | 0.83 | KCNA3 (0.69) | KCNA3ALDH1A1SMN1; SMN2HPGDBRD4 | |
| SCHEMBL11389662 | 0.81 | KCNA3 (0.74) | KCNA3ALDH1A1SMN1; SMN2HPGDBRD4 | |
| SCHEMBL11384828 | 0.79 | KCNA3 (0.64) | KCNA3ALDH1A1SMN1; SMN2HPGDBRD4 | |
| SCHEMBL11385254 | 0.79 | KCNA3 (0.77) | KCNA3ALDH1A1SMN1; SMN2HPGDBRD4 | |
| SCHEMBL16364135 | 0.78 | KCNA3 (0.63) | KCNA3ALDH1A1SMN1; SMN2HPGDBRD4 | |
| SCHEMBL11387758 | 0.78 | KCNA3 (0.80) | KCNA3ALDH1A1SMN1; SMN2HPGDBRD4 | |
| SCHEMBL30783436 | 0.78 | KCNA3 (0.61) | KCNA3ALDH1A1SMN1; SMN2HPGDBRD4 | |
| SCHEMBL11379787 | 0.78 | KCNA3 (0.61) | KCNA3ALDH1A1SMN1; SMN2HPGDBRD4 | |
| SCHEMBL25493370 | 0.77 | KCNA3 (0.78) | KCNA3ALDH1A1SMN1; SMN2HPGDBRD4 | |
| SCHEMBL11385072 | 0.77 | KCNA3 (0.78) | KCNA3ALDH1A1SMN1; SMN2HPGDBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160244435-A1 | EXPANDED THERAPEUTIC POTENTIAL IN NITROHETEROARYL ANTIMICROBIALS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2016-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160244435-A1 | EXPANDED THERAPEUTIC POTENTIAL IN NITROHETEROARYL ANTIMICROBIALS | NQO1, TXN2, MPO | KCNA3 4046/4885ALDH1A1 1589/4885SMN1; SMN2 1033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.